IKZF1 and acute lymphoblastic leukemia: Based on the negative prognostic significance of IKZF1-deleted B-ALL, several trials have utilized this approach for patients with IKZF1 deletions, including the DFCI ALL Consortium (NCT03020030), AIEOP-BFM (NCT03643276), DCOG [83], and the Malaysia-Singapore (MASPORE) leukemia study group [84] (Table 2).